Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG
This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF<sup>®</sup>01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated i...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/7/751 |
id |
doaj-ddf9ff625de74314839de7aca4cf5aa7 |
---|---|
record_format |
Article |
spelling |
doaj-ddf9ff625de74314839de7aca4cf5aa72021-07-23T14:10:41ZengMDPI AGVaccines2076-393X2021-07-01975175110.3390/vaccines9070751Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEGSergi López-Serrano0Lorena Cordoba1Mónica Pérez-Maillo2Patricia Pleguezuelos3Edmond J. Remarque4Thomas Ebensen5Carlos A. Guzmán6Dennis Christensen7Joaquim Segalés8Ayub Darji9IRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainBiomedical Primate Research Center, Department of Immunobiology, P.O. Box 3306, 2280 GH Rijswijk, The NetherlandsHelmholtz Centre for Infection Research, Department of Vaccinology and Applied Microbiology, Inhoffenstraße 7, 38124 Braunschweig, GermanyHelmholtz Centre for Infection Research, Department of Vaccinology and Applied Microbiology, Inhoffenstraße 7, 38124 Braunschweig, GermanyVirus Research and Development Laboratory, Department of Virus and Microbiological Special Diagnostics, Statens Serum Institute, Artillerivej 5, 2300 Copenhagen, DenmarkIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainIRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, SpainThis study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF<sup>®</sup>01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF<sup>®</sup>01 or NG34 + CDA/αGCM. As controls, groups of animals (<i>n</i> = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund’s adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 10<sup>6</sup> TCID<sub>50</sub>/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF<sup>®</sup>01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF<sup>®</sup>01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF<sup>®</sup>01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF<sup>®</sup>01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding.https://www.mdpi.com/2076-393X/9/7/751vaccineadjuvantsinfluenzaimmunitypathology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sergi López-Serrano Lorena Cordoba Mónica Pérez-Maillo Patricia Pleguezuelos Edmond J. Remarque Thomas Ebensen Carlos A. Guzmán Dennis Christensen Joaquim Segalés Ayub Darji |
spellingShingle |
Sergi López-Serrano Lorena Cordoba Mónica Pérez-Maillo Patricia Pleguezuelos Edmond J. Remarque Thomas Ebensen Carlos A. Guzmán Dennis Christensen Joaquim Segalés Ayub Darji Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG Vaccines vaccine adjuvants influenza immunity pathology |
author_facet |
Sergi López-Serrano Lorena Cordoba Mónica Pérez-Maillo Patricia Pleguezuelos Edmond J. Remarque Thomas Ebensen Carlos A. Guzmán Dennis Christensen Joaquim Segalés Ayub Darji |
author_sort |
Sergi López-Serrano |
title |
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG |
title_short |
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG |
title_full |
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG |
title_fullStr |
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG |
title_full_unstemmed |
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF<sup>®</sup>01 or CDA/αGalCerMPEG |
title_sort |
immune responses to pandemic h1n1 influenza virus infection in pigs vaccinated with a conserved hemagglutinin ha1 peptide adjuvanted with caf<sup>®</sup>01 or cda/αgalcermpeg |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2021-07-01 |
description |
This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF<sup>®</sup>01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF<sup>®</sup>01 or NG34 + CDA/αGCM. As controls, groups of animals (<i>n</i> = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund’s adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 10<sup>6</sup> TCID<sub>50</sub>/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF<sup>®</sup>01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF<sup>®</sup>01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF<sup>®</sup>01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF<sup>®</sup>01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding. |
topic |
vaccine adjuvants influenza immunity pathology |
url |
https://www.mdpi.com/2076-393X/9/7/751 |
work_keys_str_mv |
AT sergilopezserrano immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT lorenacordoba immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT monicaperezmaillo immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT patriciapleguezuelos immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT edmondjremarque immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT thomasebensen immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT carlosaguzman immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT dennischristensen immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT joaquimsegales immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg AT ayubdarji immuneresponsestopandemich1n1influenzavirusinfectioninpigsvaccinatedwithaconservedhemagglutininha1peptideadjuvantedwithcafsupsup01orcdaagalcermpeg |
_version_ |
1721285562239811584 |